CTOR
NASD Citius Oncology, Inc.$0.7920 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.7920, $0.0515 below the day’s high of $0.8435
- YTD change
- -20.80%
- vs 20-day SMA
- -17.83%
- vs 200-day SMA
- -8.49%
Price ranges
Price & Performance
+0.11 (+16.50%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 87.2% away from all-time highs of $6.1900
- CTOR is down 21% since the beginning of the year
- CTOR is down 54% over the past 12 months
- CTOR is down 16% over the past 1 month
- 1% of all CTOR investors are betting against CTOR
CTOR reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -54.2%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -9.33%
- vs 8-day SMA
- -9.38%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Competitor comparison
No peer group available for this symbol.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
